Summary :- Sunlenca is the First and Only Approved Capsid Inhibitor-Based HIV Treatment Option New Drug Application Approval Based on High Rates…
@2021 – All Right Reserved. Designed and Developed by Ample eBusiness
Category:
Companies
-
-
AgrochemicalsGsk
GSK and Wave Life Sciences Establish a Partnership to further the Identification and Development of Therapeutic Oligonucleotides that Target Novel Genomic Targets.
by adminby adminGSK plc (LSE/NYSE: GSK) and Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for…
-
Mirati TherapeuticsRegulatoryU.S FDA
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation
by adminby adminSummary :-Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted…
-
CompaniesPfizerRegulatoryU.S FDA
Pfizer’s Elranatamab Granted FDA Breakthrough Therapy Designation for relapsed or Refractory Multiple Myeloma
by adminby adminPfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for…
-
GskMerger / Acquisition
To Speed up R&D, GSK Announces an Expanded Partnership with Tempus in Precision Medicine.
by adminby adminGSK plc (LSE/NYSE: GSK) and Tempus, a US-based precision medicine company, have entered into a three-year collaboration agreement that provides GSK with…
-
GskWHO
WHO Grants Prequalification to GSK’s Mosquirix – the first and only approved Malaria Vaccine
by adminby adminSummary: The World Health Organization (WHO) has awarded prequalification to Mosquirix, GSK’s malaria vaccine. This is the first prequalification for a malaria vaccine…
-
Bristol Myers SquibbRegulatoryU.S FDA
Bristol Myers Squibb Notches another FDA Approval for Sotyktu™ (Deucravacitinib), Oral Treatment for Adults with Moderate-to-Severe Plaque Psoriasis
by adminby adminHighlights: Bristol Myers Squibb’s Sotyktu, a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the…
-
RegulatoryU.S FDAVertex
Vertex Announces U.S. FDA Approval for ORKAMBI® (lumacaftor/ivacaftor) in Children With Cystic Fibrosis Ages 12 to 24 months
by adminby adminSummary: Orkambi was first approved in 2015 in the US and is now available in more than 30 countries. Vertex Pharmaceuticals Incorporated…
-
Boehringer IngelheimRegulatoryU.S FDA
Boehringer’s Spevigo (spesolimab) Bags First FDA Approval for Rare Skin Disease, for Generalized Pustular Psoriasis (GPP)
by adminby adminSynopsis: German drugmaker Boehringer Ingelheim has its first regulatory approval for spesolimab, its antibody therapy for rare and life-threatening skin disorder generalised…
-
RegulatorySanofi Inc.U.S FDA
XenpozymeTM (Olipudase alfa-rpcp) Approved by FDA as First Disease-Specific Treatment for Acid Sphingomyelinase Deficiency, a Rare Genetic Disease to Sanofi
by adminby adminSummary: XenpozymeTM (olipudase alfa-rpcp) approved by FDA as first disease-specific treatment for ASMD (non-CNS manifestations) Xenpozyme is the first approved medication to treat symptoms that are not related…
Newer Posts